1stOncology™: Cancer Intelligence Service – Page 11212 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Zimmer Biomet Holdings to Present at the Bank of America Merrill Lynch 2020 Health Care Conference

On April 30, 2020 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, reported that President and CEO Bryan Hanson and Executive Vice President and Chief Financial Officer Suky Upadhyay will be participating in a fireside chat at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, at 10:20 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed via Zimmer Biomet’s Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference.

WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

On April 30, 2020 WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, reported a strategic collaboration agreement granting Aravive the right to use the proprietary WuXiBody platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis (Press release, WuXi Biologics, APR 30, 2020, View Source [SID1234556881]).

WuXi Biologics and Aravive will collaborate to discover antibodies against CCN2, a multidomain protein also known as connective tissue growth factor (CTGF). CCN2 was identified from a similar target discovery screen that identified the significance of the AXL/GAS6 pathway in cancer. Preclinical data identified CCN2 as important for tumor growth and progression.

WuXi Biologics will be responsible for biologics discovery, process development, and manufacturing. Aravive will be responsible for preclinical and clinical development. The companies did not disclose the financial terms of the collaboration.

"Aravive’s proficiency in development of anti-cancer and fibrotic drugs and WuXi Biologics’ expertise with biological discovery and manufacturing is a powerful combination," said Gail McIntyre, Ph.D., chief executive officer of Aravive. "We look forward to further expanding our collaboration to identify high affinity antibodies that can be exploited as anti-cancer and anti-fibrotic agents."

In 2018, and following the successful filing of a U.S. Investigational New Drug application (IND) for AVB-500, WuXi Biologics and Aravive announced expansion of their biologics manufacturing collaboration based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive’s lead drug candidate, AVB-500.

"We are glad to once again collaborate with Aravive as a trusted partner to accelerate the discovery, development and manufacturing of biologics through our innovative technology platforms," said Chris Chen, Ph.D., chief executive officer of WuXi Biologics. "WuXi Biologics’ proprietary antibody platforms including WuXiBody, are uniquely positioned to expedite development of novel bispecifics to benefit global patients."

About WuXiBody

WuXiBody is a leading proprietary bispecific antibody platform developed by WuXi Biologics. It can effectively break through the CMC barriers for many bispecific antibodies development with high expression yield, high stability, good solubility, and easy purification to homogeneity, expedite the process by 6-18 months and significantly reduce manufacturing costs, a limitation still faced by many other current bispecific platforms. WuXiBody Platform enables almost any mAb sequence pairs to be assembled into bispecific constructs, which are expected to have low immunogenicity risk and longer in vivo half-life. WuXiBody Platform also has a unique structural flexibility, which makes it convenient to build various formats with different combination of valencies (1+1, 1+2, 2+2) to meet the requirements of different target biologies.

Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic

On April 30, 2020 Trio Pharmaceuticals, Inc. ("TRIO"), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate (TDC) and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, reported a development collaboration agreement to evaluate AJICAP, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs (Press release, Trio Pharmaceuticals, APR 30, 2020, https://www.prnewswire.com/news-releases/trio-pharmaceuticals-inc-and-ajinomoto-bio-pharma-services-enter-into-a-development-collaboration-for-a-novel-antibody-therapeutic-301049693.html [SID1234556880]). The AJICAP technology will be used to conjugate a cytotoxic payload to TRIO’s lead oncology candidate with TRIO evaluating functionality of the TDC.

TDCs are a first-in-class ADC with dual functionality. TRIO’s dual action TDC utilizes targeted payload delivery to stop both tumor growth and immunosuppression. By generating a less immunosuppressive tumor microenvironment, TDC enhances activation of tumor-specific immune effector cells further facilitating cancer cell destruction.

AJICAP is a robust site-specific conjugation technology compatible with varied antibody modalities. AJICAP’s advantage is its "off-the-shelf" feature, allowing any antibody drug at any stage of development to be conjugated to drug-payloads of choice without the need to modify the sequence. In contrast to traditional Cys-maleimide and Lys-succinimide conjugation technologies, AJICAP conjugation is robust and generates ADCs with high yields.

"We are very excited to collaborate with Aji Bio-Pharma for evaluating AJICAP to develop our proprietary dual action TDC. The AJICAP conjugation technology marks a new beginning in the ADC field, allowing generation of ADCs with site-specific conjugation without change in antibody sequence, a rate-limiting step in the development of site-specific ADCs. Setting an early collaboration with Aji Bio-Pharma will ease our cGMP plans for clinical development," noted Dr. Shiva Bhowmik, Founder + CEO of Trio Pharmaceuticals, Inc.

Dr. Brian Mendelsohn, Director, Process Development and Technology Transfer at Aji Bio-Pharma stated, "AJICAP was developed to create novel ADCs with therapeutic window enhancements, while shortening the development timeline. We are excited to collaborate with TRIO as they advance TDC technology, developing a new class of ADCs. This collaboration marks a new avenue of development in the ADC field."

Dr. Tatsuya Okuzumi, Associate General Manager, Business Development, Ajinomoto Co, Inc., added, "We are very excited to collaborate with TRIO in the development of dual action ADCs. As a member of the Ajinomoto Group, Aji Bio-Pharma houses a talented and dedicated team of ADC scientists and strong CMC capabilities, which will benefit TRIO’s development of this novel ADC."

PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020

On April 30, 2020 PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reported that it will release its first quarter 2020 financial results for the period ended March 31, 2020, on Thursday, May 7, 2020, after market close (Press release, PDL BioPharma, APR 30, 2020, View Source [SID1234556879]). PDL’s management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at View Source

Conference Call Details
To access the live conference call via phone, please dial (844) 535-4071 from the United States and Canada or (706) 679-2458 internationally. The conference ID is 7238226. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 7238226.

To access the live and subsequently archived webcast of the conference call, go to "Events & Presentations" on the Company’s website. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

Cryoport to Report First Quarter 2020 Financial Results on May 7, 2020

On April 30, 2020 Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), a global leader in life sciences solutions, reported that the Company will report financial results for the first quarter ended March 31, 2020 on Thursday, May 7, 2020 after U.S. markets close (Press release, Cryoport, APR 30, 2020, View Source [SID1234556878]).

In addition to the earnings release, a document titled "Cryoport First Quarter 2020 in Review", providing a review of Cryoport’s recent financial and operational performance and a general business update, will be issued at 4:05 pm ET on Thursday, May 7, 2020. The document is designed to be read by investors before the questions and answers conference call and can be accessed at http://ir.cryoport.com/events-and-presentations.

Cryoport management will host a conference call at 5:00 pm ET on May 7, 2020. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results.

Conference Call Information

Date:

May 7, 2020

Time:

5:00 p.m. ET

Dial-in numbers:

+1 (855) 327-6837 (U.S.), +1 (631) 891-4304 (International)

Confirmation code:

Request the "Cryoport Call"

Live webcast:

‘Investor Relations’ section at www.cryoport.com or at this link. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

Questions and answers will be recorded and available approximately three hours after completion of the live event on the Investor Relations section of the Company’s website at www.cryoport.com for a limited time. To access the replay of the questions and answers, please follow this link. A dial-in replay of the call will also be available, to those interested, until May 14, 2020. To access the replay, dial +1 (844) 512-2921 (United States) or +1 (412) 317-6671 (International) and enter replay pin number: 10009027.